Assembly Biosciences (ASMB) vs Tectonic Therapeutic (TECX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Tectonic Therapeutic (TECX) has outperformed Assembly Biosciences (ASMB) over the past year, gaining 52.3% versus a loss of 3.8%. Over five years, ASMB leads with a -41.3% price change compared with -67.4% for TECX. Assembly Biosciences is the larger company by market cap ($467.3 million vs $444.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ASMB | TECX |
|---|---|---|
| Share price | $22.95 | $22.71 |
| Market cap | $467.28M | $443.97M |
| 1-day change | +3.47% | +1.34% |
| YTD return | -32.52% | +8.87% |
| 1-year return | -3.81% | +52.31% |
| 5-year return | -41.33% | -67.37% |
| P/E ratio (TTM) | 22.07 | — |
| EPS (TTM) | $1.04 | $-4.57 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $39.71 | $39.53 |
| 52-week low | $21.80 | $15.32 |
| Distance from 52-week high | -42.21% | -42.55% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +126.58% | +237.43% |
| Average volume | 277.22K | 219.12K |
| Shares outstanding | 20.36M | 19.55M |
| Employees | 73 | 60 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TECX has outperformed ASMB by 56.1 percentage points over the past year.
About Assembly Biosciences
ASMB stock →Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection.
Healthcare · Biotechnology · 73 employees
About Tectonic Therapeutic
TECX stock →Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines.
Healthcare · Biotechnology · 60 employees
ASMB vs TECX FAQ
Which is bigger, Assembly Biosciences or Tectonic Therapeutic?
Assembly Biosciences (ASMB) is larger, with a market capitalization of $467.28M compared with $443.97M for Tectonic Therapeutic (TECX).
Which stock has performed better over the past year, ASMB or TECX?
TECX returned +52.31% over the past 12 months, compared with -3.81% for ASMB (price return, excluding dividends). Past performance does not predict future results.
Are Assembly Biosciences and Tectonic Therapeutic in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.